Page 86 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

62 David S. Younger

[229] Martinez, V., Cohen, P., Pagnoux, C., et al., for the French Vasculitis Study Group.
Intravenous immunoglobulin for relapses of systemic vasculitides associated with
antineutrophil cytoplasmic antibodies. Arthritis Rheum. 2008; 58:308-317.

[230] Langford, C. A. Perspectives on the treatment of giant cell arteritis [Abstract]. Presse
Med. 2013; 42:609-612.

[231] Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., et al. Infliximab for maintenance of
glucocorticoid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern.
Med. 2007; 146:621-630.

[232] Novikov, P., Smitienko, I., Moiseev, S. Efficacy of long-term treatment with TNF
inhibitors in patients with refractory Takayasu arteritis [Abstract]. Presse Med. 2013;
42:723.

[233] Youngstein, T., Peters, J., Mason, J. Biologic agents offer an effective long-term
therapeutic option for refractory Takayasu arteritis [Abstract]. Presse Med. 2013; 42:
677-678.

[234] Abisror, N., Mekinian, A., Lavigne, C., et al. Tocilizumab in refractory Takayasu
arteritis: case series and literature review [Abstract]. Presse Med. 2013; 42:725-726.

[235] Sciascia, S., Piras, D., Baldovino, S., et al. Mycophenolate mofetil as steroid-sparing
treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin.
Exp. Res. 2012; 24:273-277.

[236] Nesher, G., Berkun, Y., Mates, M., et al. Low-dose aspirin and prevention of cranial
ischemic complications in giant cell arteritis. Arthritis Rheum. 2004; 50:1332-1337.

[237] Lee, M. S., Smith, S. D., Galor, et al. Antiplatelet and anticoagulant therapy in patients
with giant cell arteritis. Arthritis Rheum. 2006; 54:3306-3309.

[238] Fernanda, F., Serena, C., Giustina, R., et al. Mycophenolate mofetil treatment in two
children with severe polyarteritis nodosa refractory to immunosuppressant drugs.
Rheumatol. Int. 2012; 32:2215-2219.

[239] Cordier, J.-F. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) [Abstract].
Presse Med. 2013; 42:507-510.

[240] Little, M. A., Nightingale, P., Verburgh, C. A., et al. Early mortality in systemic
vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum.
Dis. 2009; 69:1036-1043.

[241] Jayne, D. Rituximab for ANCA-associated vasculitis: the UK experience [Abstract].
Presse Med. 2013; 42:532-534.

[242] Brihaye, B., Aouba, A., Pagnoux, C., et al. Adjunction of rituximab to steroids and
immunosuppressants for refractory/relapsing Wegener?s granulomatosis: a study on 8
patients. Clin. Exp. Rheumatol. 2007; 25:523-527.

[243] Charles, P., Guillevin, L. Rituximab for ANCA-associated vasculitides: the French
experience. Presse Med. 2013; 42:534-536.

[244] Han, F., Liu, G., Zhang, X., et al. Effects of mycophenolate mofetil combined with
corticosteroids for induction therapy of microscopic polyangiitis. Am. J. Nephrol. 2011;
33:185-192.

[245] Ostojic, P. Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with
mycophenolate mofetil. Rheumatol. Int. 34:145-147.

[246] Conlon, K. C., Urba, W. J., Smith, J. W., et al. Exacerbation of symptoms of
autoimmune disease in patients receiving alpha interferon therapy. Cancer 1990; 65:
2237-2242.

Complimentary Contributor Copy